Individuelle Therapieziele bei Typ-2-Diabetes im mittleren Erwachsenenalter
作者： S. Matthaei , F. Thienel
DOI: 10.1007/S11428-011-0814-9
关键词: Gynecology 、 Medicine 、 Ldl cholesterin
摘要: Die Steno-2-Studie hat gezeigt, dass durch eine multifaktorielle Therapie der Patienten mit Typ-2-Diabetes, die das Erreichen Therapieziele fur HbA1c, Blutdruck und LDL-Cholesterin sowie den Einsatz niedrig-dosierter Acetylsalicylsaure (ASS) anstrebt, sowohl makro- als auch mikrovaskulare Komplikationen effektiv reduziert werden konnen. Da diese etwa 50% gesamten Kosten ausmachen, ware langfristig neben Linderung individuellen Leids Kostenreduktion zu erwarten.
springer.com
sci-hub.se 参考文章(20)
H.-U. Häring, H.-G. Joost, M. Kellerer, Ch. Kloos, T. Kunt, M. Nauck, G. Schernthaner, E. Siegel, F. Thienel, S. Matthaei, R. Bierwirth, A. Fritsche, B. Gallwitz, Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Experimental and Clinical Endocrinology & Diabetes. ,vol. 117, pp. 522- 557 ,(2009) , 10.1055/S-0029-1239559
Maria Carla Roncaglioni, None, Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general Practice The Lancet. ,vol. 357, pp. 89- 95 ,(2001) , 10.1016/S0140-6736(00)03539-X
R. S. Elkeles, J. R. Diamond, C. Poulter, S. Dhanjil, A. N. Nicolaides, S. Mahmood, W. Richmond, H. Mather, P. Sharp, M. D. Feher, , Cardiovascular Outcomes in Type 2 Diabetes: A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study Diabetes Care. ,vol. 21, pp. 641- 648 ,(1998) , 10.2337/DIACARE.21.4.641
Joann E Manson, Diederick E Grobbee, Meir J Stampfer, James O Taylor, Samuel Z Goldhaber, J Michael Gaziano, Paul M Ridker, Julie E Buring, Charles H Hennekens, None, Aspirin in the primary prevention of angina pectoris in a randomized trial of United States physicians The American Journal of Medicine. ,vol. 89, pp. 772- 776 ,(1990) , 10.1016/0002-9343(90)90220-8
Helen M Colhoun, D John Betteridge, Paul N Durrington, Graham A Hitman, H Andrew W Neil, Shona J Livingstone, Margaret J Thomason, Michael I Mackness, Valentine Charlton-Menys, John H Fuller, CARDS investigators, None, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial The Lancet. ,vol. 364, pp. 685- 696 ,(2004) , 10.1016/S0140-6736(04)16895-5
Irene M Stratton, Amanda I Adler, H Andrew W Neil, David R Matthews, Susan E Manley, Carole A Cull, David Hadden, Robert C Turner, Rury R Holman, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ. ,vol. 321, pp. 405- 412 ,(2000) , 10.1136/BMJ.321.7258.405
John R. Downs, Michael Clearfield, Stephen Weis, Edwin Whitney, Deborah R. Shapiro, Polly A. Beere, Alexandra Langendorfer, Evan A. Stein, William Kruyer, Antonio M. Gotto, Jr, for the AFCAPS/TexCAPS Research Group, Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels JAMA. ,vol. 279, pp. 1615- 1622 ,(1998) , 10.1001/JAMA.279.20.1615
Kalevi Pyörälä, Christie M Ballantyne, Barry Gumbiner, Michael W Lee, Arvind Shah, Michael J Davies, Yale B Mitchel, Terje R Pedersen, John Kjekshus, Scandinavian Simvastatin Survival Study Group, Reduction of Cardiovascular Events by Simvastatin in Nondiabetic Coronary Heart Disease Patients With and Without the Metabolic Syndrome Subgroup analyses of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care. ,vol. 27, pp. 1735- 1740 ,(2004) , 10.2337/DIACARE.27.7.1735
Lennart Hansson, Alberto Zanchetti, S George Carruthers, Björn Dahlöf, Dag Elmfeldt, Stevo Julius, Joël Ménard, Karl Heinz Rahn, Hans Wedel, Sten Westerling, THE HOT INVESTIGATORS, including F Portaluppi, None, Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial The Lancet. ,vol. 351, pp. 1755- 1762 ,(1998) , 10.1016/S0140-6736(98)04311-6